The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.50BCNY
1.12B · vs all stocks (USD)
Updated Oct 24, 2026
Revenue (TTM)
1.01BCNY
151.76M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
-45.36%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.3850x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-33.54%
vs all stocks
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
7.50BCNY
1.12B · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
7.87BCNY
1.18B · vs all stocks (USD)
Updated Oct 24, 2026
Forward P/E
-25.50x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Sales (TTM)
7.10x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 7.41×.Updated Oct 24, 2026
Price to Book (MRQ)
57.99x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
7.78x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to EBITDA
-20.71x
vs Biotechnology peers
Updated Oct 24, 2026
Gross Margin
79.70%
vs Biotechnology peers
Updated Oct 24, 2026
Profit Margin
-45.36%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
-35.90%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
-12.94%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
-129.83%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
1.01BCNY
151.76M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
2.45CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
13.40%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
810.59MCNY
121.57M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
-380.00MCNY
-56.99M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
-458.98MCNY
-68.84M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
29.24%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
63.73MCNY
9.56M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
-243.60MCNY
-36.54M · vs all stocks (USD)
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Trailing Annual Dividend Rate
0.00CNYUpdated Oct 24, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue
935.22MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
197.22MCNYFY2025 · Dec 31, 2025
Gross Profit
738.00MCNYFY2025 · Dec 31, 2025
Operating Income
-346.27MCNY
-51.93M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-331.65MCNYFY2025 · Dec 31, 2025
Income Tax Expense
292.39KCNYFY2025 · Dec 31, 2025
Net Income
-331.94MCNYFY2025 · Dec 31, 2025
EBIT
-311.58MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-205.98MCNYFY2025 · Dec 31, 2025
Research & Development
800.15MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
273.32MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
9.25MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.85MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
20.07MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.8000CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.8000CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-331.94MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-536.13MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-657.69MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
218.61MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-331.94MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
21.26MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-166.03MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-59.42MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-121.56MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-880.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
971.75MCNYFY2025 · Dec 31, 2025
Other Investing Activity
21.11MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-8.69MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
360.27MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-298.53MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-20.39MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-58.00KCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
41.29MCNYFY2025 · Dec 31, 2025
Shares Outstanding
414.08MSharesUpdated Oct 24, 2026
Float Shares
115.66MSharesUpdated Oct 24, 2026
% Held by Insiders
70.87%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
6.17%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
395.52MCNY
59.32M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
0.9550CNYUpdated Oct 24, 2026
Total Debt (MRQ)
898.00MCNY
134.68M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
7.25x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
0.6500x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
0.2990CNYUpdated Oct 24, 2026
Total Assets
2.29BCNY
343.05M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
958.56MCNYFY2025 · Dec 31, 2025
Total Liabilities
1.91BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.33BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
543.94MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.37BCNYFY2025 · Dec 31, 2025
Cash
218.61MCNYFY2025 · Dec 31, 2025
Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
218.61MCNYFY2025 · Dec 31, 2025
Accounts Receivable
164.70MCNYFY2025 · Dec 31, 2025
Inventory
312.42MCNYFY2025 · Dec 31, 2025
Accounts Payable
198.69MCNYFY2025 · Dec 31, 2025
Short-term Debt
311.83MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
703.48KCNYFY2025 · Dec 31, 2025
Long-term Debt
374.21MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
144.81MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
414.08MCNYFY2025 · Dec 31, 2025
Retained Earnings
-3.09BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
376.03MCNY
56.40M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
15.57CNYUpdated Oct 24, 2026
52-Week High
27.84CNYUpdated Oct 24, 2026
52-Week Change
-33.54%
vs all stocks
Updated Oct 24, 2026
Beta
0.3850x
vs all stocks
Updated Oct 24, 2026
50-Day MA
19.05CNYUpdated Oct 24, 2026
200-Day MA
20.34CNYUpdated Oct 24, 2026
Avg 10-Day Volume
3.58MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
4.05MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
-1.11CNYUpdated Oct 24, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Debt is a large share of its assets, and large against its cash flow.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.65×, lower than 95% of its Biotechnology peers (median 5.17×)Significant
Current ratio: 0.65Industry median: 5.17Industry P5: 1.15Peers compared: 184
Debt-to-equity is 7.25×, higher than 95% of its Biotechnology peers (median 0.11×)Significant